ENTITY

Shenzhen Immunofoco (2633140D HK)

4
Analysis
Health Care • China
Shenzhen Immunofoco Biotechnology Co., Ltd. develops innovative cell therapies. The Company produces anti-CLDN18.2 CAR-T cell therapy candidate (IMC002) for treatment of solid tumors and anti-EpCAM CAR-T cell therapy candidate (IMC001). Shenzhen Immunofoco Biotechnology conducts businesses in China.
more
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
x